Lupus Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others), By Route of Administration (Oral, Intravenous, Subcutaneous), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, By Competition

According to Lupus Foundation of America, at least five million people worldwide have a form of lupus and the disease is more prevalent among the people belonging to age group 15-44

Lupus has no known cure, but treatments can help manage symptoms.

Increasing Prevalence of Lupus propels the market growth for Lupus Therapeutics

According to a research article, “Global epidemiology of systemic lupus erythematosusa comprehensive systematic analysis and modelling study”, Systemic lupus erythematosus (SLE), is the most common type of lupus. The incidence of SLE in the general population varied from 1.18 (0.16 to 3.68) per 100 000 person-years in central Asia to 13.74 (3.2 to 31.82) per 100 000 person-years in central Europe. The top four countries with the highest estimates of SLE incidence were Poland followed by United States, Barbados, and China

Rising Research and Development in Drug Discovery drives Global Lupus Therapeutics Market

Lupus

As of 9th May 2023, as per clinicaltrials.gov, there are around 278 studies in different phases of development related to Lupus Therapeutics worldwide.

Recent Development

• In July 2022, GlaxoSmithKline,plc new launch Benlysta (belimumab) has been given the approval by the US Foodand Drug Administration (FDA) for the treatment of active lupus nephritis (LN)in children aged 5 to 17 who are receiving standard therapy. Currently, the only biologic approvedfor use in both adults and children with lupus or lupus nephritis is Benlysta.
• In March 2023, The LupusResearch Alliance (LRA) has been established by the Lupus Accelerating BreakthroughsConsortium (Lupus ABC) and the US Food and Drug Administration (FDA) in aneffort to advance research for the condition. According to the FDA, Lupus ABC will bring perspectives to acentralized forum to define drug development challenges and examine potentialsolutions to advance therapies.

Mergers, Acquisitions and Collaborations

• InJune 2021, Progentec collaborated with GlaxoSmithKline, plc for an 18-monthagreement to research new systemic lupus erythematosus (SLE or lupus) measurementand management tools. 
• InJanuary 2023, EVOQ Therapeutics launched its collaboration and licensingagreement with Gilead Sciences to advance the latter's technology and createimmunotherapies for the treatment of lupus. In accordance with the terms of theagreement, the two businesses will collaborate to advance the preclinicaldevelopment of immunotherapies for RA and lupus.

Market Segmentation

Global Lupus Therapeutics Market is segmented based on

Market players

GlaxoSmithKline, plc., Novartis AG, AstraZeneca, plc., Hoffmann-La Roche AG, Eli Lilly and Company. ImmuPharma PLC, Pfizer, Inc., Sanofi S.A., Bristl Myers Squibb Company, Merck & Co., Inc. are the key players operating in the global lupus therapeutics market.